Mumbai, Baltimore, January 25, 2021: Lupin Limited (Lupin), global pharmaceutical company, announced today that it has received approval for its Sevelamer Carbonate Tablets, 800 mg, from the United States Food and Drug Administration, to market a generic equivalent of Renvela® Tablets, 800 mg, of Genzyme Corporation.
Sevelamer Carbonate Tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis.
Sevelamer Carbonate Tablets (RLD: Renvela®) had estimated annual sales of USD 348 million in the U.S. (IQVIA MAT September 2020).
Are you an aspiring enthusiast willing to develop a career in the medical sales field? The dynamic profile of a medical representative, their exponent...
A healthy gut indicates a healthy you! Isn't that true? In easy words, gut health refers to the balance of microorganisms present in your digestive sy...
Is the scorching sun heat taking a toll on your skin health? The summers trigger all skin types due to excessive humidity and heat around. Dermatologi...
